Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology
Disease area: Airway diseases, Paediatric lung diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
H. Grasemann, N. McDonald, S. Dell, F. Ratjen (Toronto, Canada). L-Arginine metabolism in airways of children with primary ciliary dyskinesia (PCD) or cystic fibrosis (CF). Eur Respir J 2014; 44: Suppl. 58, 1204

Member's Comments

No comment yet.

Related content which might interest you: Differences in airway inflammation between children with primary ciliary dyskinesia (PCD) and cystic fibrosis (CF) Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014 Nasal nitric oxide measurement and a score of key clinical features for the screening of primary ciliary dyskinesia in patients with non-cystic fibrosis bronchiectasis Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Airway nitric oxide production in patients with cystic fibrosis increases with ivacaftor therapy Source: International Congress 2015 – Cystic fibrosis: assessment and treatment Year: 2015 Differences in exhaled nitric oxide levels between patients with cystic fibrosis and atopic bronchial asthma Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013 Fractional exhaled nitric oxide levels in patients with non-cystic fibrosis bronchiectasis Source: International Congress 2016 – Asthma, bronchiectasis, and the risk factors for respiratory morbidity Year: 2016 Exhaled nitric oxide is not reduced in infants with cystic fibrosis Source: Eur Respir J 2006; 27: 350-354 Year: 2006 Effect of inhaled L-arginine on airway nitric oxide in cystic fibrosis patients Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005 Bronchial but not alveolar nitric oxide is decreased in adults with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 404s Year: 2005 Evaluation of exhaled nitric oxide in idiopathic interstitial lung diseases Source: International Congress 2015 – IIPs: orphan Year: 2015 LATE-BREAKING ABSTRACT: A relative plasma Elafin deficiency in children with cystic fibrosis (CF) is associated with pulmonary disease Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014 Chest Vest therapy increases FENO and may lead to F508del CFTR maturation Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment Year: 2014 Polymorphisms in NOS-1 and NOS-3 genes may influence the cystic fibrosis severity? Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014 Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study Source: Eur Respir J 2005; 25: 62-68 Year: 2005 Increased systemic inflammation in cystic fibrosis (CF) is associated with deterioration in lung clearance index (LCI) Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014 Exhaled nitric oxide in respiratory diseases other than asthma Source: Eur Respir Monogr 2010; 49: 45-55 Year: 2010 Measurement of alveolar nitric oxide in IPF patients and in healthy controls Source: International Congress 2014 – ILDs 4 Year: 2014 Glucocorticoid treatment reduces exhaled nitric oxide in cystic fibrosis patients Source: Eur Respir J 2001; 17: 1267-1270 Year: 2001 Airway acidification and exhaled nitric oxide in cystic fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 514s Year: 2003 Plasma asymmetric dimethylarginine (ADMA) in pediatric patients with cystic fibrosis (CF) Source: International Congress 2016 – Systemic biomarkers Year: 2016 Lung function and early abnormality of glucose tolerance (GT) in cystic fibrosis (CF) patients Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013